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Abstract Why and how HIV makes people sick is highly
debated. Recent evidence implicates heightened immune
activation due to breakdown of the gastrointestinal barrier
as a determining factor of lentiviral pathogenesis. HIV-
mediated loss of Th17 cells from the gut-associated
lymphoid tissue (GALT) impairs mucosal integrity and
innate defense mechanisms against gut microbes. Translo-
cation of microbial products from the gut, in turn, correlates
with increased immune activation in chronic HIV infection
and may further damage the immune system by increasing
viral and activation-induced T cell death, by reducing T cell
reconstitution due to tissue scarring, and by impairing the
function of other cell types, such as γδ T cells and
epithelial cells. Maintaining a healthy GALT may be the
key to reducing the pathogenic potential of HIV.
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Introduction
HIV infection is characterized by a progressive immunodefi-
ciency, which is reflected in a steady decline of CD4+ T cells.
Disease progression varies considerably from patient to patient.
Some develop the acquired immunodeficiency syndrome
(AIDS) after a few months; others remain healthy for decades.
Such a disparity also exists in monkeys of distinct species
infected with simian immunodeficiency virus (SIV). SIV
infection of African monkeys, the natural hosts for SIV, does
not result in simian AIDS, but SIV infection of most Asian
monkeys rapidly progresses to AIDS [43]. Remarkably, despite
25 years of HIV and SIV research, the reasons for these
differences in disease outcome are only partially understood.
To design new treatment approaches, including vaccination or
eradication strategies, we need to understand the basis for
these disparities.
Immune dysfunction and disease onset cannot be
explained solely by the direct cytopathic effect of the virus.
Other factors have been implicated in T cell loss, such as
the killing of infected cells by cytotoxic T cells, bystander
death of uninfected cells due to HIV products, and T cell
dysfunction and death due to heightened levels of immune
activation [52]. A hyperactive immune state with high T
cell turnover, polyclonal activation of B cells, and elevated
proinflammatory cytokines is characteristic of HIV infec-
tion [52]. In fact, the activation status of CD8+ T cells is
one of the best predictors of disease progression [28].
While the association of immune activation and HIV
infection is well known, its causes are only partially
understood.
A recent model links disturbance of the gut-associated
lymphoid tissue (GALT) to immune activation and lenti-
viral disease progression [6]. The GALT is one of the
primary organs affected by HIV and SIV, and GALT
lymphocytes are the primary target cells of HIV during
mucosal transmission. After rectal exposure, they are the
first immune cells that encounter HIV. For infections by
different routes, they form a large pool of HIV target cells,
in which HIV efficiently spreads and replicates. Later on,
during chronic HIV infection, loss of GALT integrity may
have a major impact on AIDS pathogenesis [40]. Briefly,
during the chronic phase of infection, elevated levels of
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microbial products are found in the systemic circulation,
and these levels correlate with immune activation and
disease state. Initial studies looking at interactions of
lentiviruses with the GALT focused mainly on numbers of
infected and dying T cells. Recently, studies have proposed
cellular and molecular mechanisms that clarify the intricate
role of GALT in HIV pathogenesis. Here, we will review
these studies and relate their findings to lentiviral disease
progression.
Profound depletion of GALT lymphocytes occurs
during acute lentiviral infection
The CD4+ T cell count in the blood is a commonly used
clinical marker for monitoring progression rate in HIV
infection. In acute HIV infection, blood CD4+ T cell
numbers may decline sharply, but as soon as an antiviral
immune response is established, blood CD4+ T cells have
the potential to recover. Subsequently, during chronic HIV
infection, blood CD4+ T cell counts decline slowly, but this
loss can be partially reversed by successful antiretroviral
treatment. However, T cells in the GALT display entirely
different kinetics: in SIV-infected macaques and in HIV-
infected humans, CD4+ T cells of the lamina propria are
rapidly and profoundly depleted in the first days after
infection, and their numbers remain low throughout the
course of disease [34, 51, 54]. Even after years of
antiretroviral therapy, this loss is only partially reversible
in most patients [17, 35]. Thus, lymphocyte depletion in the
GALT is a distinct feature of lentiviral infection.
The pronounced loss of GALT lymphocytes probably
occurs because the majority of newly transmitted HIV
strains use CCR5 as a coreceptor for cell entry [2]. A high
percentage of CD4+ T cells in the intestinal effector sites
are CCR5-positive memory cells, and, thus, GALT lym-
phocytes are ideal viral targets. In contrast, many T cells in
blood and lymph nodes are naive and hence CCR5 negative
[41]. During acute SIV infection, up to 60% of all memory
CD4+ T cells in the jejunum harbor HIV DNA [33],
suggesting that direct viral cytopathic effects cause the
massive loss of CD4+ T cells during acute infection.
Furthermore, high levels of Fas-mediated apoptosis of
infected and uninfected CD4+ T cells occur during peak
viremia [26]. Direct viral killing and bystander death of
uninfected cells wipe out most of the CD4+ memory cell
population in the GALT.
When the loss of GALT lymphocytes was first discov-
ered, it appeared plausible that this defect in mucosal
immune surveillance would have dire consequences for the
whole immune system and would influence disease
progression. Surprisingly, however, SIV depletes lamina
propria T cells in all monkey species, irrespective of
whether they will develop simian AIDS or not. Natural
SIV hosts, such as sooty mangabeys and African green
monkeys, do not progress to AIDS despite high viral loads,
but rhesus macaques infected with the same SIV strain
show blood CD4+ T cell loss and disease progression,
closely resembling HIV pathogenesis in humans [43]. In
both the pathogenic and nonpathogenic SIV model, GALT
CD4+ T cells are lost at similar rates during acute infection
[15, 42]. At later times, however, the GALT can be partially
restored in the nonpathogenic models. These observations
indicate that acute intestinal CD4+ T cell loss is a basic
feature of lentiviral infections but is not predictive of later
disease outcome. Low numbers of GALT lymphocytes per
se do not make animals or humans sick; additional factors
are important for the pathogenic potential of HIV.
In chronic lentiviral infection, circulating microbial
products are associated with immune activation
Differences in pathogenic and nonpathogenic SIV models
become more apparent when GALT function, rather than
simple lymphocyte numbers, is considered. The GALT
prevents microbial invasions from the intestinal lumen. In
chronic lentiviral infections, this function seems to be
disturbed, and more microbial products are found in the
systemic circulation.
Brenchely et al. [7] measured plasma levels of
lipopolysaccharide (LPS), a component of gram-
negative bacterial cell walls, as an indicator of microbial
translocation from the gut. They found higher plasma
LPS levels in chronically HIV-infected patients than in
healthy subjects. Notably, a similar LPS increase was
observed in the pathogenic SIV rhesus macaque model.
In contrast, in the nonpathogenic SIV sooty mangabey
model, LPS levels were low, irrespective of SIV status.
Thus, in SIV-infected sooty mangabeys, GALT immune
function appears to be sufficient to prevent increases of
bacterial products in the systemic circulation despite
intestinal CD4+ T cell depletion.
To further elucidate the connection between clinical
outcome and microbial translocation, plasma LPS levels
were examined in defined subsets of patients. For example,
Hunt et al. [21] verified a finding from Brenchely et al. [7]:
HIV-infected elite controllers—patients with undetectable
viral loads without antiretroviral treatment—have LPS
levels similar to patients with higher viral loads. At first
glance, these data might indicate that no connection
between plasma LPS and disease outcome exists. However,
Hunt et al. showed that plasma LPS in elite controllers
correlated with immune activation, which was associated
with lower CD4+ T cell counts. This finding suggests that,
in elite controllers, immune activation is detrimental and
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leads to CD4+ T cell loss, despite suppressed plasma viral
load, and that bacterial translocation may be the activating
factor.
Marchetti et al. [32] investigated bacterial translocation
in patients on highly active antiretroviral therapy
(HAART). All patients on HAART had lower plasma
levels of LPS than untreated control patients. As defined by
blood CD4+ T cell reconstitution, therapy success was
associated with even lower LPS levels. Patients who did not
show T cell recovery despite suppressed HIV RNA had
more bacterial translocation as quantified by plasma LPS
than patients who responded immunologically and virolog-
ically to HAART. This means that in both groups with
suppressed viral loads—either in elite controllers or in
HAART-treated patients—low-level microbial translocation
still occurs and seems to be associated with lower CD4+ T
cell counts.
In support of the link between bacterial translocation and
HIV pathogenesis, Ancuta et al. [1] found higher plasma
LPS levels in patients with HIV-associated dementia than in
HIV-positive patients without neurocognitive impairment.
They proposed LPS-mediated monocyte activation and
trafficking to the brain as the underlying mechanisms of
this association between LPS and dementia. As supporting
evidence, they showed upregulation of activation markers
on monocytes and increases of soluble CD14, interleukin
(IL)-6, and CCL2 in the plasma of HIV-infected patients.
To further investigate the effects of bacterial transloca-
tion on immune activation, Gregson et al. [16] compared
plasma LPS levels in HIV-infected individuals to HIV-
negative patients with active colitis, either colitis ulcerosa
or morbus Crohn. All groups had similarly elevated LPS
levels. However, colitis usually shows a fluctuating course:
the gastrointestinal barrier, in fact, is only affected during
an inflammatory phase but is relatively intact between flare-
ups. In contrast, HIV-infected patients seem to experience
constant bacterial translocation and immune activation.
However, factors other than bacterial translocation are
thought to contribute to sustained immune activation. In
particular, Gregson et al. reported that the activated phenotype
of NK cells seen in their cohort of HIV-positive patients was
linked to the plasma viral load and not to plasma LPS.
Strikingly, the colitis patients, which had LPS levels as high as
the HIV-positive patients, showed only low numbers of
activated CD8+ T cells, indicating that high levels of plasma
LPS alone do not cause activation of CD8+ T cells.
A study in patients undergoing interruption of antire-
troviral therapy [44] supports the notion that CD8+ T cell
activation not only depends on plasma LPS. In the first
6 weeks after stopping HAART, LPS levels remained
unchanged, whereas percentages of activated blood CD8+
T cells increased. Only later did plasma LPS levels rise, but
still no association with activated CD8+ T cells was
detected, perhaps because the study examined a relatively
small population. Interestingly, the delayed onset of LPS
increase after treatment interruption mirrors the initial
findings of Brenchely et al. [7], which also showed that,
for LPS to increase, some time of sustained viral replication
was required. Plasma LPS levels were similar in patients
with acute HIV infection and in healthy control subjects. A
possible explanation is that, initially, systemically circulat-
ing LPS can be cleared, but, over time, this function is
impaired. The treatment interruption study showed a
negative correlation between changes of plasma LPS levels
and endotoxin core antibodies (EndoCAb) in the early
phase, when plasma LPS levels are controlled. Later on,
this correlation is lost. They claimed that, initially, LPS is
cleared by EndoCAb, and EndoCAb levels therefore
decrease. After some time, clearance is no longer effective,
due either to excessive microbial translocation or to
inadequate B cell function.
In conclusion, there is universal agreement that heightened
levels of circulating bacterial products correlate in general with
immune activation in pathogenic lentiviral infections (Table 1).
However, careful interpretation is needed when deducing the
mechanistic links between these events. A direct causative
relation has not been established between heightened LPS
levels and HIV disease progression. In an alternative
explanation, microbial translocation may be an epiphenome-
non of an activated and dysfunctional immune system.
Also, what is the deficit in the GALT resulting in bacterial
translocation? Recent studies propose a mechanism linking
depletion of a subset of GALT effector site lymphocytes,
namely Th17 cells, with breakdown of the gastrointestinal
barrier. Such a link is a first step in explaining the relationships
between HIV infection and GALT dysfunction.
Th17 cell help is essential for the integrity
of the gastrointestinal barrier
Th17 cells are important for intestinal homeostasis
(reviewed in [30]). Briefly, this subset of CD4+ T cells is
characterized by the production of IL-17 in response to
stimulation, but they also secrete other cytokines, including
tumor necrosis factor (TNF)-α, IL-1, IL-6, IL-21, and IL-
22. Their strong proinflammatory properties are both
beneficial and harmful. Initial animal studies identified
Th17 cells as important mediators of autoimmune disease
and tissue damage [24, 58], yet, with their ability to recruit
neutrophils [57], they also are important for controlling
infections by bacteria and fungi [18–20, 22, 31, 56].
Furthermore, Th17 cells are involved in epithelial regener-
ation [5]. They stimulate production of defensins and mucin
[11, 53], and they induce the expression of claudins [23],
which are components of epithelial tight junctions. Finally,
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IL-22, an important Th17 cytokine, increases the produc-
tion of LPS binding protein (LBP) in the liver [55].
Considering the massive CD4+ T cell depletion in the
lamina propria after HIV infection, it is reasonable to
assume that Th17 cells are also depleted by HIV. And with
their multiple functions in controlling epithelial integrity
and microbial invasion, their loss likely affects the integrity
of the gastrointestinal barrier.
While Th17 cells are permissive to HIV infection in vitro,
they do not appear to be the preferential targets of HIV [8] nor
of SIV [9]. Infection rates are similar in all CD4+ T cells,
irrespective of Th17 or Th1 differentiation. Nevertheless, in
acutely SIV-infected rhesus macaques, the intestinal Th17
responses seem to be afflicted more than the Th1 response.
Checchinato et al. [9] found that the percentage of IL-17-
producing cells, as related to all intestinal CD4+ T cells, was
much lower, whereas the percentage of interferon-γ-
producing cells was much greater than in healthy animals.
Relative numbers, however, do not take into account the
massive reduction of absolute CD4+ T cell numbers in the gut
during acute SIV infection. Even though relative numbers of
Th1 cells may be increased, the absolute numbers are still
strongly reduced. It is difficult to judge the importance of
relative differences between Th17 and Th1 responses in light
of the overall loss of lymphocytes.
Brenchley et al. [8] further investigated the effects of HIV
infection on T cell subsets at different mucosal surfaces and
compared T cell responses in lung and gut. In contrast to
results from bronchoalveolar lavage samples, they found a
preferential depletion of IL-17-producing CD4+ T cells in the
gut of HIV-infected humans. This result indicates that HIV
infection especially reduces the intestinal Th17 function. In
contrast to reports in humans, in SIV-infected sooty manga-
beys, the relative numbers of IL-17+ CD4+ T cells in the gut
are similar to those in uninfected animals. The authors linked
this intact Th17 function in SIV-infected sooty mangabeys
with their nonpathogenic phenotype. Again, one should be
careful in interpreting relative cell numbers from the gut
because of the overall depletion of CD4+ T cells.
Still, the data from both these studies suggest that the
intestinal Th17 response is diminished during lentiviral
infection, probably due to depletion or dysfunction of these
Table 1 Bacterial translocation in lentiviral infections
Study Subjects Parameters Results
Ancuta
et al. [1]
HIV in humans: progressors with or
without HIV-associated dementia
LPS, sCD14, LBP, EndoCAb, IL-6,
CCL2, CD16+, CD69+, or CCR5+
monocytes
Higher LPS levels in patients with dementia,
association between monocyte activation, LPS,
and dementia
Brenchley
et al. [7]
HIV in humans: negative, acute/
early, chronic, AIDS
LPS, sCD14, LBP, EndoCAb, LPS
reactivity of monocytes ex vivo, plasma
IFN-α, CD8+ HLA DR+ CD38+ T cells
Higher LPS levels in chronic infection, correlation
with immune activation
HIV in humans: negative, before
and after HAART
LPS decrease under HAART, but no normalization
HIV in humans: negative,
controllers, progressors
Higher LPS levels in controllers compared to
uninfected subjects, no significant difference to
progressors
SIV in rhesus macaques: negative,
positive, positive treated with
antibiotics
LPS increase after SIV infection in RMs, reduction
under antibiotics
SIV in sooty mangabeys: negative,
positive
Low LPS levels in both groups of SMs
Gregson
et al. [16]
HIV in humans: negative, untreated/
viremic, HAART colitis: active
Crohn’s disease or colitis ulcerosa
LPS, CD8+ HLA DR+ CD38+ T cells,
NK cell activation, LPS reactivity of
NK cells ex vivo
Higher LPS levels in HIV-infected, irrespective of
HAART, no difference of LPS levels between
HIV-infected and colitis patients, NK and CD8+
T cell activation in HIV-infected patients, not in
colitis patients
Hunt
et al. [21]
HIV in humans: negative,
controllers, progressors
LPS, CD8+ HLA DR+ CD38+ T cells Higher LPS levels in controllers compared to
uninfected subjects, no significant difference to
progressors, correlation between activated CD8+
T cells and LPS in controllers
Marchetti
et al.
[32]
HIV in humans: untreated/
advanced, HAART/full
responders, HAART/
immunological nonresponders
LPS, bacterial 16sRNA, CD4+ and CD81
Ki67+ T cells
Treatment reduced LPS levels overall, but
immunological nonresponders had higher levels
than full responders
Papasavvas
et al. [44]
HIV in humans: HAART before and
after short/long-time treatment
interruption
LPS, sCD14, LBP, EndoCAb, CD8+
CD38+ T cells
No LPS increase after short-time treatment inter-
ruption, but already increase of CD8+ T cell
activation; after long-time treatment interruption,
LPS increase
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cells. What are now the consequences of an impaired Th17
response in the gut? Raffatellu et al. [46] addressed this
question in an elegant study using a gut ligation model in
rhesus macaques to study Salmonella translocation. Indi-
vidual intestinal loops from the same animal are either
mock inoculated or exposed to Salmonella, and immune
responses then can be quantified. Intestinal Salmonella
inoculation induced a strong mucosal Th17 response in this
model. This Th17 response, however, was blunted when the
rhesus macaques were chronically SIV-infected. Conse-
quently, SIV-infected rhesus macaques had a greater degree
of Salmonella translocation to mesenteric lymph nodes than
SIV-negative monkeys. One could argue that this effect of
the SIV infection on immune control of Salmonella
translocation may not be Th17 specific but rather is due
to overall GALT depletion. But Raffatellu et al. confirmed
their data in mice with a targeted defect in the IL-17
receptor. Due to abrogated IL-17 signaling, these mice had
less production of other IL-17-dependent cytokines upon
gastrointestinal Salmonella inoculation, they recruited less
neutrophils to the mucosa, and they were unable to control
Salmonella translocation. The data from Raffatellu et al.
corroborate the current view that HIV infection results in a
loss of the intestinal Th17 response and that this affects the
integrity of the gastrointestinal barrier.
In conclusion, these studies propose a model in which HIV/
SIV-mediated Th17 depletion fromGALTeffector sites impairs
the gastrointestinal barrier. This, in turn, leads to translocation
of intestinal microbes or microbial products, which then
contribute to immune activation (Fig. 1). However, we must
be aware that no definitive experimental proof links Th17
dysfunction and elevated LPS levels. Increased intestinal
Salmonella invasion after SIV infection is an intriguing hint
but not the same as continuous translocation of harmless
commensal bacteria. In Cecchinato et al. [9], for example, no
correlation between LPS levels and GALT Th17 cell numbers
was found in SIV-infected macaques. Nevertheless, Th17 cells
probably are important in overall immunodeficiency. Recent-
ly, a defect in Th17 differentiation in patients with autosomal
dominant hyper-Ig-E syndrome [36] was identified. Hyper-Ig-
E syndrome is characterized by Candida infections, recurring
pneumonia, skin abscesses, and lymphomas—a clinical
picture reminiscent of AIDS. However, no data exist on the
integrity of the gastrointestinal barrier and bacterial transloca-
tion in these patients.
A disturbed gastrointestinal barrier may have negative
effects on the immune system
While circulating microbial products correlate well with
activation markers on immune cells, the exact connection
between these two phenomena is not clear. Does immune
activation render the immune system so dysfunctional that
it can no longer control bacterial translocation, or do the
circulating bacteria and bacterial components activate the
immune system and thereby contribute to the progressive
immunodeficiency observed in HIV? Both possibilities
likely coexist, leading to a vicious circle in which one
factor triggers the other one. In any case, sustained immune
activation has negative effects on T cell function and
survival. For one, sustained activation provides a large pool
of activated CD4+ T cells, which are optimal viral targets
since HIV more efficiently infects and replicates in
activated CD4+ T cells [12]. However, in most of the
above studies, no positive association between plasma viral
load and LPS was found [7, 44]. This is not surprising since
many other factors besides overall activation status can
influence viral load (e.g., HIV-specific immune responses,
chemokine levels, and viral fitness).
In addition to providing a continuous reservoir of
optimally activated HIV target cells, microbial products
may initiate activation-induced cell death. An innovative
study by Bourgeois et al. [4] in mice showed that naive
CD4+ T cells are especially affected by activation-induced
cell death from gut antigens. While investigating peripheral
T cell dynamics after thymic ablation, they found a
substantial decay in naive CD4+ T cells, while CD8+ T
cell counts remained relatively stable. As the cause of CD4
+ T cell activation and subsequent activation-induced death
of naive cells, they identified translocation of microbial
products from the gut. Indeed, the mice had higher levels of
LBP, an acute-phase protein produced in the liver after
exposure to LPS. Notably, in transfer experiments, they
established that those CD4+ T cells reactive to gut microbes
and involved in intestinal inflammation were lost specifi-
cally. Induction of intestinal inflammation by transfer of T
cells reactive to gut microbes is an established tool in colitis
research [29]. Naive CD4+ T cells depleted of CD25 high
cells are transferred into immunodeficient mice; there, they
proliferate and respond to intestinal antigens. Bourgeois et
al. [4] found that CD4+ T cells from donor mice with
bacterial translocation could no longer induce colitis in the
recipient mice. Because of the antigen recognition and
activation mechanisms in CD4+ T cells, these cells may be
especially prone to effects from microbial translocation.
Microbial products circulate in the extracellular compart-
ment and are taken up by antigen-presenting cells for
processing and presentation on major histocompatibility
(MHC) class II molecules. Thereby, CD4+ T cells (i.e.,
those cells recognizing antigen in the context of MHC II)
but not CD8+ T cells are activated and die.
HIV infection likely influences other immune cells in the
GALT. For example, T regulatory cells (Tregs) are also
affected. Tregs are abundant in the intestinal mucosa and are
involved in maintaining a healthy balance between tolerance
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and immune control of gut microbes. Highly viremic SIV-
infected macaques have more mucosal Tregs than animals with
low viral loads [3]. These numerous Tregs may contribute to a
less efficient SIV-specific immune response and consecutively
to increased SIV loads. However, this hypothesis is contro-
versial. Another study showed that inhibiting Treg function
with a blocking antibody to CTLA-4 increased SIV replica-
tion, particularly at mucosal sites [10]. This study suggests
that Tregs are protective by reducing immune activation and
viral replication. Thus, increased Treg numbers in highly
Fig. 1 HIV infection depletes
lymphocytes, including Th17
cells, from the GALT effector
sites. Th17 cells are essential in
maintaining an intact gastroin-
testinal barrier against gut
microbes by producing cyto-
kines that are essential for epi-
thelial regeneration and
neutrophil recruitment. In HIV-
positive individuals, circulating
microbial products can be
detected, and these levels corre-
late with immune activation
Fig. 2 Microbial translocation
and ensuing immune activation
can damage the immune system
and contribute to HIV patho-
genesis. By increasing numbers
of activated cells, which are
preferentially infected, microbial
translocation can increase viral
replication. Furthermore, acti-
vated cells are prone to
activation-induced cell death,
and immune reconstitution is
limited due to fibrosis of the
lymphatic tissue. Other immune
cells, such as macrophages or
γδ T cells, also are negatively
affected by lentiviral infection
and may be dysfunctional. Epi-
thelial disturbance is also ob-
served in HIV infection
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viremic macaques may represent a negative regulatory
feedback mechanism.
The GALT contains many cell types besides classical
CD4+ T cells (e.g., plasma cells, dendritic cells, monocytes,
or γδ T cells). Little is known about their fates during
chronic lentiviral infection. Some studies suggest that they
may be essential for limiting microbial translocation. In
addition to depletion of Th17 cells, Brenchley et al. [8] also
noted loss of myelomonocytic cells in the GALT of HIV-
infected individuals. These myelomonocytic cells, which
include granulocytes, macrophages, and dendritic cells, are
essential for killing and phagocytosis of gut microbes, and
for orchestrating an adaptive immune response. Another
hint for the involvement of additional GALT cells in
controlling microbial translocation comes from one of the
nonpathogenic SIV models: sooty mangabeys, which do
not show prolonged systemic LPS increases despite GALT
CD4+ T cell depletion, have astoundingly high numbers of
γδ T cells [7]. γδ T cells build an interface between innate
and adaptive immunity and are essential for immune
function at mucosal surfaces [38]. Therefore, they may
have a protective effect on integrity of the intestinal barrier
and may limit bacterial translocation. Compared to humans,
sooty mangabeys have higher numbers of γδ T cells, and
their γδ T cell response to bacterial antigens is even
enhanced [37] after SIV infection. In contrast, in HIV-
infected humans, γδ T cell counts are lower, and the cells
are anergic to stimulation with mycobacterial antigens [45].
HIV infection also interferes with stromal and epithelial
cells of the intestinal mucosa. During acute SIV infection,
massive apoptosis occurs in the gut epithelium [27].
Proinflammatory genes are upregulated, and genes respon-
sible for epithelial regeneration and digestive/metabolic
functions are downregulated [47]. Notably, in chronic
infection, a proinflammatory milieu marked by upregula-
tion of IL-6 and STAT3 persists [39], and mucosal IL-2, IL-
4, and TNF-α are increased, leading to increased epithelial
permeability [13]. Intestinal inflammation and epithelial
apoptosis not only impairs the gastrointestinal barrier,
chronic inflammation also has negative effects on overall
tissue architecture. GALT tissue from HIV-infected patients
shows marked fibrosis, and the amount of collagen
deposition is even higher than in other lymphatic organs
[14]. In lymph nodes, intense fibrosis correlates with low
CD4+ T cell counts and poor T cell reconstitution under
HAART [49, 50], and the same very likely applies to GALT
fibrosis. This observation explains the slow and poor
reconstitution of GALT lymphocytes under HAART,
despite suppression of the local mucosal inflammation and
permeability changes mediated by successful antiretroviral
treatment [13].
In summary, accumulating data indicate that HIV causes
a profound and complex disturbance of the mucosal
immune function. The detrimental effects of HIV are not
limited to CD4+ T cells. In chronic HIV infection, disturbed
GALT function and microbial translocation are accompa-
nied by an incessant vicious circle of immune activation
and inflammation with deleterious consequences on viral
replication, T cell and epithelial cell death, and dysfunction
of multiple additional cells (Fig. 2).
Conclusions
The GALT is one of the major organs affected by HIV
infection. Viral replication and T cell loss are even more
pronounced in the intestinal lamina propria than in other
lymphoid tissues. Furthermore, in chronic HIV infection, a
poorly controlled translocation of bacterial products (e.g.,
LPS) occurs and correlates with immune activation
markers, which in turn are associated with disease
progression. Recently, a handful of studies identified the
critical role of Th17 cells in this process. During pathogenic
lentiviral infections, Th17 function in the GALT is reduced
and invasion of gut bacteria—directly shown so far only
with Salmonella—is increased.
However, many questions remain. Cause and effect
relations in this circle of immune dysfunction and
bacterial translocation are difficult to pin down. Conse-
quently, one cannot predict if reduction of bacterial
translocation or immune activation would be a beneficial
therapeutic approach. Studies with compounds blocking
immune activation so far did not show positive effects [25,
48], maybe due to a general immunosuppressive effect of
these drugs. Despite reduced immune activation, which
may prevent further deterioration of immune functions,
such drugs will also reduce immune responses directed
against the virus. The optimal therapy should reduce the
damaging general activation of immune cells, boost HIV-
specific immune responses, and activate antimicrobial
defenses at mucosal surfaces to reduce translocation of
gut microbes.
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